This is the first case report describing a complete response to bicalutamide withdrawal that lasted for almost 2 years in a patient with metastatic prostate cancer. An 80-year-old man who had prostatespecific antigen (PSA) level elevation (168.1 ng/mL) visited our hospital in February 2010. Bone scintigraphy showed pelvic metastases. We started hormonal therapy with leuprorelin and bicalutamide. The PSA concentration decreased to <0.1 ng/mL but started increasing again and reached 1.64 ng/mL in October 2012, at which time bicalutamide administration was discontinued. The PSA concentration decreased again and has remained below the limit of sensitivity for almost 2 years.
Introduction
Cancer of the prostate is the most prevalent cancer in American men. Metastatic prostate cancer is primarily treated by testicular androgen ablation (medical or surgical). Nonsteroidal antiandrogens are commonly used with luteinizing hormonee releasing hormone analogs for metastatic prostate cancer.
Withdrawal responses after estrogenic therapy for breast cancer were reported in 1986. Withdrawal responses in prostate cancer patients were initially documented after treatment with flutamide. 1 Since then, withdrawal responses after other antiandrogens have been reported in prostate cancer cases. 2 Some cases respond well to antiandrogen withdrawal, with a >50% decline in prostate-specific antigen (PSA) level, but the duration of remission is limited to approximately 6 months.
We report here a patient with metastatic prostate cancer who had complete remission for almost 2 years after bicalutamide withdrawal.
Case presentation
An 80-year-old man visited our hospital in February 2006 for further evaluation of PSA level elevation, which was 168.1 ng/mL. A stony hard nodule was found in the right lobe of the prostate on digital rectal examination. The patient had hip pain. We strongly suspected metastatic prostate cancer. We scheduled a prostate biopsy within a few weeks, but he experienced an acute myocardial infarction and was admitted to the cardiovascular department of our hospital before the biopsy. Magnetic resonance imaging performed during hospitalization showed a gadolinium-enhanced tumor with a low T2 signal in the right lobe of the prostate. Bone scintigraphy showed metastatic tumors in the hip bone and pubis ( Fig. 1 ). We made a diagnosis of poorly differentiated prostate cancer based on a physical examination and imaging test without the prostate biopsy because of the limitations of the indication. Hormonal therapy with leuprorelin and bicalutamide was started. The PSA concentration decreased to <0.1 ng/mL in 3 months, but started increasing again from the beginning of 2010, and reached 1.64 ng/mL in October 2012. The hip pain worsened and the alkaline phosphatase level rose to 453 IU/L. Bicalutamide administration was discontinued. The PSA concentration started declining again after a month, and dropped to <0.01 ng/mL within 3 months. The pain was resolved and the alkaline phosphatase concentration decreased to a normal level. The concentration of testosterone remained under 0.1 ng/mL after bicalutamide withdrawal. The PSA concentration has remained below the limit of sensitivity till date, which is almost 2 years (Fig. 2) .
Discussion
Antiandrogen withdrawal syndrome with flutamide was first reported in 1993. 1 Since then, withdrawal responses after other antiandrogens have been reported in prostate cancer cases. 
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Conclusion
We have described a patient whose PSA level remained below the limit of sensitivity for almost 2 years after bicalutamide withdrawal. Further study of the antiandrogen withdrawal response rate and the duration of PSA decline for each drug withdrawal is needed, which may contribute information concerning the choice of firstline antiandrogen drugs.
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